Matches in Wikidata for { <http://www.wikidata.org/entity/Q90835967> ?p ?o ?g. }
Showing items 1 to 33 of
33
with 100 items per page.
- Q90835967 description "artículu científicu espublizáu en mayu de 2019" @default.
- Q90835967 description "im Mai 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q90835967 description "scientific article published on 01 May 2019" @default.
- Q90835967 description "wetenschappelijk artikel" @default.
- Q90835967 description "наукова стаття, опублікована 1 травня 2019" @default.
- Q90835967 name "A SPECIAL MEETING REVIEW EDITION: Highlights in Inflammatory Bowel Disease From the 14th Congress of ECCO: A Review of Selected Presentations From the 14th Congress of the European Crohn's and Colitis Organisation (ECCO) • March 6-9, 2019 • Copenhag" @default.
- Q90835967 name "A SPECIAL MEETING REVIEW EDITION: Highlights in Inflammatory Bowel Disease From the 14th Congress of ECCO: A Review of Selected Presentations From the 14th Congress of the European Crohn's and Colitis Organisation (ECCO) • March 6-9, 2019 • Copenhag" @default.
- Q90835967 type Item @default.
- Q90835967 label "A SPECIAL MEETING REVIEW EDITION: Highlights in Inflammatory Bowel Disease From the 14th Congress of ECCO: A Review of Selected Presentations From the 14th Congress of the European Crohn's and Colitis Organisation (ECCO) • March 6-9, 2019 • Copenhag" @default.
- Q90835967 label "A SPECIAL MEETING REVIEW EDITION: Highlights in Inflammatory Bowel Disease From the 14th Congress of ECCO: A Review of Selected Presentations From the 14th Congress of the European Crohn's and Colitis Organisation (ECCO) • March 6-9, 2019 • Copenhag" @default.
- Q90835967 prefLabel "A SPECIAL MEETING REVIEW EDITION: Highlights in Inflammatory Bowel Disease From the 14th Congress of ECCO: A Review of Selected Presentations From the 14th Congress of the European Crohn's and Colitis Organisation (ECCO) • March 6-9, 2019 • Copenhag" @default.
- Q90835967 prefLabel "A SPECIAL MEETING REVIEW EDITION: Highlights in Inflammatory Bowel Disease From the 14th Congress of ECCO: A Review of Selected Presentations From the 14th Congress of the European Crohn's and Colitis Organisation (ECCO) • March 6-9, 2019 • Copenhag" @default.
- Q90835967 P1433 Q90835967-4F45384E-E377-4F16-BA63-BF57A7582929 @default.
- Q90835967 P1476 Q90835967-40608783-9F75-471B-BF94-07ABEF4E9496 @default.
- Q90835967 P304 Q90835967-846C6386-FA5C-4B4E-AE91-6DACF18CA36D @default.
- Q90835967 P31 Q90835967-71FCE467-AADD-4DDF-AF82-BB97627B9757 @default.
- Q90835967 P433 Q90835967-0F6E05BF-C182-4FC5-A875-F6963B60F47B @default.
- Q90835967 P478 Q90835967-EB9FB5FE-1812-4A37-BA51-413B078A7CB7 @default.
- Q90835967 P577 Q90835967-A238CBD2-42F0-4AC2-BFAC-5297E2B251B4 @default.
- Q90835967 P698 Q90835967-FD7167B8-4576-4199-AA28-49491A3FB52C @default.
- Q90835967 P921 Q90835967-2CB4E484-514F-4074-81F1-6586E786E7D1 @default.
- Q90835967 P932 Q90835967-8F9C5346-52AF-4F80-9944-C63504FC57B8 @default.
- Q90835967 P698 31632213 @default.
- Q90835967 P1433 Q26842161 @default.
- Q90835967 P1476 "A SPECIAL MEETING REVIEW EDITION: Highlights in Inflammatory Bowel Disease From the 14th Congress of ECCO: A Review of Selected Presentations From the 14th Congress of the European Crohn's and Colitis Organisation (ECCO) • March 6-9, 2019 • Copenhagen, DenmarkSpecial Reporting on:• VARSITY: A Double-Blind, Double-Dummy, Randomized Controlled Trial of Vedolizumab Versus Adalimumab in Patients With Active Ulcerative Colitis• Analyses of Data From the VISIBLE 1 and 2 Trials: Vedolizumab in Patients With Ulcerative Colitis or Crohn's Disease• Improved Endoscopic Outcomes and Mucosal Healing of Upadacitinib as an Induction Therapy in Adults With Moderately to Severely Active Ulcerative Colitis: Data From the U-ACHIEVE Study• Long-Term Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease: Final Results From the GEMINI LTS Study• Pediatric Crohn's Disease Adalimumab Level-Based Optimization Treatment (PAILOT) Randomized Controlled Trial• Maintenance Treatment With Mirikizumab, a P19-Directed IL-23 Antibody: 52-Week Results in Patients With Moderately to Severely Active Ulcerative Colitis• Real-World Effectiveness and Safety of Vedolizumab and Anti-TNF Therapy in Biologic-Naive Patients With Ulcerative Colitis or Crohn's Disease: Results From the EVOLVE Study• A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of a Targeted-Release Oral Cyclosporine Formulation in the Treatment of Mild to Moderate Ulcerative Colitis: Efficacy Results• R" @default.
- Q90835967 P304 "1-24" @default.
- Q90835967 P31 Q13442814 @default.
- Q90835967 P433 "5 Suppl 2" @default.
- Q90835967 P478 "15" @default.
- Q90835967 P577 "2019-05-01T00:00:00Z" @default.
- Q90835967 P698 "31632213" @default.
- Q90835967 P921 Q917447 @default.
- Q90835967 P932 "6794565" @default.